Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638724 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL435808 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL453487 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| Ribitol SCHEMBL28092351 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL630930 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL28129954 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL468450 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL2766970 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL21610 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL7861936 | 0.98 | PGD (0.52) | PGDMPIPGK1PGK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665401-A1 | DRUG AND TREATMENT METHOD | RadioVaxx GmbH (DE) | 2025-12-24 | — | — | EP | claimed |
| US-12268738-B2 | Liquid six combined vaccine composition | KM BIOLOGICS CO., LTD. (JP) | 2025-04-08 | — | — | US | claimed |
| US-12090195-B2 | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2024-09-17 | — | — | US | claimed |
| WO-2024170652-A1 | DRUG AND TREATMENT METHOD | RADIOVAXX GMBH (DE) | 2024-08-22 | — | — | WO | claimed |
| US-11793869-B2 | Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | SERUM INSTITUTE OF INDIA PVT LTD. (IN) | 2023-10-24 | — | — | US | claimed |
| EP-3530285-B1 | METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT | KM BIOLOGICS CO LTD (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-4047097-A1 | METHOD FOR THE PRODUCTION, RECOVERY AND PURIFICATION OF CAPSULAR POLYSACCHARIDE POLYRIBOSYLRIBITOL PHOSPHATE (PRP) AND USE THEREOF | INSTITUTO BUTANTAN (BR) | 2022-08-24 | — | — | EP | claimed |
| CN-114867864-A | Processes for the production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphate (PRP) and uses thereof | 布坦坦研究所 | 2022-08-05 | — | — | CN | claimed |
| WO-2022114735-A1 | QUALITY EVALUATION METHOD FOR PROCESS OF PURIFYING PRP ANTIGEN OF HAEMOPHILUS INFLUENZAE TYPE B | 주식회사 엘지화학 | 2022-06-02 | — | — | WO | claimed |
| CN-105805426-B | Pipeline runs through device | 上海火克新材料有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-1221664-C | Production of five-carbon sugars and sugar alcohols | DANISK SWEETENER OY (FI) | 2005-10-05 | — | — | CN | claimed |
| CN-1395618-A | Production of five carbon sugars and sugar alcohols | DANISK SWEETENER OY (FI) | 2003-02-05 | — | — | CN | claimed |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12617873-B2 | Method of purifying polysaccharides | LONZA LTD (CH) | 2026-05-05 | — | — | US | disclosed |
| WO-2026087718-A1 | A MULTIVALENT SHIGELLA VACCINE AND METHODS OF MAKING AND USING THEREOF | INSTITUT PASTEUR (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-20030068791-A1 | Manufacture of five-carbon sugars and sugar alcohols | XYROFIN OY | 2003-04-10 | — | — | US | disclosed |
| CN-1395618-A | Production of five carbon sugars and sugar alcohols | DANISK SWEETENER OY (FI) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254244-A2 | MANUFACTURE OF FIVE-CARBON SUGARS AND SUGAR ALCOHOLS | Danisco Sweeteners Oy (FI) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001053306-A2 | MANUFACTURE OF FIVE-CARBON SUGARS AND SUGAR ALCOHOLS | DANISCO SWEETENERS OY (FI) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PSEN1, CD44, CD47 | PGD 211/4885MPI 135/4885PGK1 3466/4885 |
| US-12617873-B2 | Method of purifying polysaccharides | CD47, CD69, CFB | PGD 4441/4885MPI 1567/4885PGK1 4117/4885 |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | CSGALNACT1, LY96, C5AR2 | PGD 754/4885MPI 472/4885PGK1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.